The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Empagliflozin Increases Cardiac Energy Production in Diabetes
Open accessAbstract
SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular mortality in individuals with type 2 diabetes, although the mechanism(s) of this benefit remain poorly understood. Because changes in cardiac bioenergetics play a critical role in the pathophysiology of heart failure, the authors evaluated cardiac energy production and substrate use in diabetic mice treated with the SGTL2 inhibitor, empagliflozin. Empagliflozin treatment of diabetic db/db mice prevented the development of cardiac failure. Glycolysis, and the oxidation of glucose, fatty acids and ketones were measured in the isolated working heart perfused with 5 mmol/l glucose, 0.8 mmol/l palmitate, 0.5 mmol/l ß-hydroxybutyrate (ßOHB), and 500 μU/ml insulin. In vehicle-treated db/db mice, cardiac glucose oxidation rates were decreased by 61%, compared with control mice, but only by 43% in empagliflozin-treated diabetic mice. Interestingly, cardiac ketone oxidation rates in db/db mice decreased to 45% of the rates seen in control mice, whereas a similar decrease (43%) was seen in empagliflozin-treated db/db mice. Overall cardiac adenosine triphosphate (ATP) production rates decreased by 36% in db/db vehicle-treated hearts compared with control mice, with fatty acid oxidation providing 42%, glucose oxidation 26%, ketone oxidation 10%, and glycolysis 22% of ATP production in db/db mouse hearts. In empagliflozin-treated db/db mice, cardiac ATP production rates increased by 31% compared with db/db vehicle-treated mice, primarily due to a 61% increase in the contribution of glucose oxidation to energy production. Cardiac efficiency (cardiac work/O 2 consumed) decreased by 28% in db/db vehicle-treated hearts, compared with control hearts, and empagliflozin did not increase cardiac efficiency per se. Because ketone oxidation was impaired in db/db mouse hearts, the authors determined whether this contributed to the decrease in cardiac efficiency seen in the db/db mouse hearts. Addition of 600 μmol/l ßOHB to d b/db mouse hearts perfused with 5 mmol/l glucose, 0.8 mmol/l palmitate, and 100 μU/ml insulin increased ketone oxidation rates, but did not decrease either glucose oxidation or fatty acid oxidation rates. The presence of ketones did not increase cardiac efficiency, but did increase ATP production rates, due to the additional contribution of ketone oxidation to energy production. The authors conclude that empagliflozin treatment is associated with an increase in ATP production, resulting in an enhanced energy status of the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Self-citationSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Self-citationThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Buchanan, J., Mazumder, P. K., Hu, P., Chakrabarti, G., Roberts, M. W., Yun, U. J., Cooksey, R. C., Litwin, S. E., & Abel, E. D. (2005) · Endocrinology · doi:10.1210/en.2005-0938 · Cited by 555
Mitochondrial energy metabolism in heart failure: a question of balance
Huss, J. M., & Kelly, D. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524405 · Cited by 533
Loss of Metabolic Flexibility in the Failing Heart
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00068 · Cited by 442
Self-citationMazumder, P. K., O’Neill, B. T., Roberts, M. W., Buchanan, J., Yun, U. J., Cooksey, R. C., Boudina, S., & Abel, E. D. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2366 · Cited by 437
Packer, M., Anker, S. D., Butler, J., Filippatos, G., & Zannad, F. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 336
Verma, S., Garg, A., Yan, A. T., Gupta, A. K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 232
Self-citationAlrob, O. A., Sankaralingam, S., Ma, C., Wagg, C. S., Fillmore, N., Jaswal, J. S., Sack, M. N., Lehner, R., Gupta, M. P., Michelakis, E. D., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu156 · Cited by 221
Self-citationMetabolic Origins of Heart Failure
Wende, A. R., Brahma, M. K., McGinnis, G. R., & Young, M. E. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.009 · Cited by 207
Mori, J., Patel, V. B., Abo Alrob, O., Basu, R., Altamimi, T., DesAulniers, J., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D., & Oudit, G. Y. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.000672 · Cited by 192
Self-citationSIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells
Ozden, O., Park, S.-H., Wagner, B. A., Yong Song, H., Zhu, Y., Vassilopoulos, A., Jung, B., Buettner, G. R., & Gius, D. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.001 · Cited by 188
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 171
Self-citationMori, J., Alrob, O. A., Wagg, C. S., Harris, R. A., Lopaschuk, G. D., & Oudit, G. Y. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00636.2012 · Cited by 168
Self-citationVerma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166
Self-citationBasu, R., Oudit, G. Y., Wang, X., Zhang, L., Ussher, J. R., Lopaschuk, G. D., & Kassiri, Z. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00452.2009 · Cited by 161
Self-citationVerma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158
Self-citationZhabyeyev, P., Gandhi, M., Mori, J., Basu, R., Kassiri, Z., Clanachan, A. S., Lopaschuk, G. D., & Oudit, G. Y. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs424 · Cited by 152
Self-citationSGLT-2 Inhibitors and Cardiovascular Risk
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Wilding, J. P. H., Khunti, K., Fu, A. Z., Bodegård, J., Blak, B. T., Wittbrodt, E. T., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.085 · Cited by 138
Lopaschuk, G. D., Witters, L. A., Itoi, T., Barr, R. L., & Barr, A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47327-9 · Cited by 137
Self-citationEmpagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 134
Self-citationDyck, J. R. B., Barr, A., Barr, R. L., Kolattukudy, P. E., & Lopaschuk, G. D. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.275.6.h2122 · Cited by 132
Self-citationVerma, S., Mazer, C. D., FITCHETT, D. H., Inzucchi, S. E., Pfarr, E., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4644-9 · Cited by 127
Self-citationJavadov, S. A., Huang, C., Kirshenbaum, L. A., & Karmazyn, M. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.10.007 · Cited by 81
Shi, X., Verma, S., Yun, J., Brand‐Arzamendi, K., Singh, K. K., Liu, X., Garg, A., Quan, A., & Wen, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3018-9 · Cited by 76
Self-citationThe isolated working mouse heart: methodological considerations
Larsen, T. S., Belke, D. D., Sas, R., Giles, W. R., Severson, D. L., Lopaschuk, G. D., & Tyberg, J. V. (1999) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050870 · Cited by 67
Self-citationAcetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism
Fukushima, A., Zhang, L., Huqi, A., Lam, V. H., Rawat, S., Altamimi, T., Wagg, C. S., Dhaliwal, K. K., Hornberger, L. K., Kantor, P. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99239 · Cited by 39
Self-citationSingh, K. K., Shukla, P. C., Yanagawa, B., Quan, A., Lovren, F., Pan, Y., Wagg, C. S., Teoh, H., Lopaschuk, G. D., & Verma, S. (2013) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.12.046 · Cited by 30
Self-citationCanagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
Sherman, S. E., Bell, G. I., Teoh, H., Al-Omran, M. A., Connelly, K. A., Bhatt, D. L., Hess, D. A., & Verma, S. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.010 · Cited by 24
Self-citationPrevention of Heart Failure With SGLT-2 Inhibition
Farkouh, M. E., & Verma, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.078 · Cited by 13
Self-citation
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Self-citationEpicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01536-x · Cited by 618
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Self-citation
Metadata
- Authors
- Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., Lehrke, M., Marx, N., & Lopaschuk, G. D.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 3
- Issue
- 5
- Pages
- 575-587
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W2888544493
- Cited by
- 386
- References
- 37
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.